MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, c2002-
    • Subject Terms:
      MicroRNAs/*genetics ; NF-kappa B/*metabolism ; Proto-Oncogene Proteins c-ret/*genetics ; Receptor, Notch1/*metabolism ; Transcription Factor HES-1/*metabolism; 3' Untranslated Regions ; Carcinoma, Neuroendocrine/genetics ; Carcinoma, Neuroendocrine/metabolism ; Carcinoma, Neuroendocrine/pathology ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Humans ; Models, Biological ; NF-kappa B/genetics ; Neoplasm Invasiveness ; Proto-Oncogene Mas ; Proto-Oncogene Proteins c-ret/metabolism ; RNA Interference ; Signal Transduction ; Thyroid Neoplasms/genetics ; Thyroid Neoplasms/metabolism ; Thyroid Neoplasms/pathology
    • Abstract:
      Background: Dominant-activating mutations in the RET proto-oncogene, a receptor tyrosine kinase, are responsible for the development of medullary thyroid carcinoma (MTC) and causative for multiple endocrine neoplasia (MEN) type 2A and 2B. These tumors are highly aggressive with a high propensity for early metastasis and chemoresistance. This attribute makes this neoplasia an excellent model for probing mechanisms underlying cancer progression.
      Methods: The expression level of miR-182 was measured in MTC tumor specimens and in TT cells by real-time RT-PCR. TT cells and modified NThy-ori 3.1 that stably express RETM918T were used to investigate RET-dependent regulation of miR-182. Identification and validation of miR-182 targets and pathways was accomplished with luciferase assays, qRT-PCR, Western blotting and immunofluorescence. In vitro, overexpression and knockdown experiments were carried out to examine the impact of miR-182 and HES1 on invasion and migration.
      Results: We found that miR-182 expression is significantly upregulated in MTC patient samples and tumor-derived cell lines harboring mutated RET. Inhibition of RET oncogenic signaling through a dominant-negative RET∆TK mutant in TT cells reduces miR-182, whereas overexpression of RETM918T in NThy-ori 3.1 cells increases miR-182 levels. We further show that overexpression of this miRNA in NThy.miR-182 cells promotes the invasive and migratory properties without affecting cell proliferation. MiR-182 is upregulated after RET induced NF-κB translocation into the nucleus via binding of NF-κB to the miR-182 promoter. Database analysis revealed that HES1, a repressor of the Notch pathway, is a target of miR-182, whose upregulation correlates with loss of HES1 transcription in MTC tissue samples and mutant RET cell lines. Moreover, we demonstrated that the 3'UTR of the HES1 mRNA bearing the targeting sequence for miR-182 clearly reduced luciferase reporter activity in cells expressing miR-182. Decreased expression of HES1 promotes migration by upregulating Notch1 inhibitor Deltex1 and consequent repression of Notch1.
      Conclusion: We demonstrate a novel mechanism for MTC aggressiveness in which mutated RET/NF-κB-driven expression of miR-182 impedes HES1 activation in a negative feedback loop. This observation might open new possibilities to treat RET oncogene associated metastatic cancer.
    • References:
      J Surg Res. 2011 Nov;171(1):23-7. (PMID: 21571316)
      Clin Cancer Res. 2011 Jul 15;17(14):4772-81. (PMID: 21622722)
      Thyroid. 2015 Jun;25(6):567-610. (PMID: 25810047)
      Cancer Lett. 2015 Jun 28;362(1):97-105. (PMID: 25813403)
      Genes Dev. 2015 Apr 1;29(7):732-45. (PMID: 25838542)
      Eur J Endocrinol. 2015 May;172(5):R215-25. (PMID: 25572389)
      Lab Invest. 2008 Jan;88(1):11-7. (PMID: 18059366)
      Oncogene. 2010 May 20;29(20):2916-26. (PMID: 20208568)
      J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9. (PMID: 15316058)
      Cancer Cell. 2014 Mar 17;25(3):318-34. (PMID: 24651013)
      Hum Gene Ther. 2003 Jul 1;14(10):971-82. (PMID: 12869215)
      Eur J Endocrinol. 2016 Sep;175(3):173-80. (PMID: 27283290)
      Cancer Biol Ther. 2015 ;16(3):353-9. (PMID: 25781910)
      Nat Rev Cancer. 2014 Mar;14(3):173-86. (PMID: 24561444)
      J Clin Invest. 2014 Oct;124(10):4305-19. (PMID: 25180607)
      FEBS Lett. 2014 May 2;588(9):1644-51. (PMID: 24631532)
      Hum Pathol. 2015 Jan;46(1):50-7. (PMID: 25316501)
      Mol Cell Endocrinol. 2010 May 28;321(1):29-35. (PMID: 19879919)
      J Biol Chem. 2015 May 29;290(22):13812-29. (PMID: 25873390)
      BMC Cancer. 2012 Jun 08;12:227. (PMID: 22681717)
      Anticancer Res. 2015 Apr;35(4):2037-47. (PMID: 25862858)
      Am J Respir Crit Care Med. 2015 Jul 1;192(1):64-75. (PMID: 25906011)
      J Clin Invest. 2012 Oct;122(10 ):3563-78. (PMID: 23006329)
      J Clin Endocrinol Metab. 2013 Jan;98 (1):E1-7. (PMID: 23150679)
      Cancer Immunol Res. 2014 Sep;2(9):823-30. (PMID: 25187272)
      Clin Exp Metastasis. 2015 Feb;32(2):169-79. (PMID: 25636905)
      Cancer Manag Res. 2015 Aug 19;7:265-78. (PMID: 26316818)
      Clin Endocrinol (Oxf). 2011 Dec;75(6):801-5. (PMID: 21711375)
      Nat Clin Pract Oncol. 2006 Oct;3(10):564-74. (PMID: 17019434)
      Hum Pathol. 2008 Jul;39(7):994-1001. (PMID: 18508109)
      Oncologist. 2008 Feb;13(2):98-104. (PMID: 18305053)
      Diagn Pathol. 2014 Jul 10;9:143. (PMID: 25012722)
      J Cell Physiol. 2003 Mar;194(3):237-55. (PMID: 12548545)
      Am J Transl Res. 2010 Feb 10;2(1):119-25. (PMID: 20182588)
      Cancer Res. 2001 Jun 1;61(11):4526-35. (PMID: 11389085)
      Oncogene. 2006 Oct 26;25(50):6637-47. (PMID: 16715139)
      Oncotarget. 2015 Nov 3;6(34):36713-30. (PMID: 26452025)
      Pharmacol Ther. 2011 Jul;131(1):18-32. (PMID: 21514318)
      Cancer. 2014 Jul 1;120(13):1920-31. (PMID: 24699901)
      Oncogene. 2008 Sep 18;27(42):5643-7. (PMID: 18504431)
      J Clin Endocrinol Metab. 2010 Mar;95(3):1421-30. (PMID: 20061417)
      Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9. (PMID: 19188590)
      Curr Opin Genet Dev. 2013 Feb;23(1):3-11. (PMID: 23465882)
      Biochem Biophys Res Commun. 2014 Jul 18;450(1):857-62. (PMID: 24971532)
      Cancer Med. 2015 Feb;4(2):174-82. (PMID: 25487826)
      J Biol Chem. 2006 Dec 29;281(52):39819-30. (PMID: 17090547)
      Acta Neuropathol. 2012 Apr;123(4):539-52. (PMID: 22402744)
      Curr Protoc Hum Genet. 2007 Jul;Chapter 12:Unit 12.10. (PMID: 18428406)
      Thyroid. 2012 Sep;22(9):890-6. (PMID: 22747440)
      J Clin Endocrinol Metab. 2014 Dec;99(12 ):4390-6. (PMID: 25238206)
      Curr Opin Oncol. 2006 Jan;18(1):30-5. (PMID: 16357561)
      Breast Cancer Res. 2014 Nov 14;16(6):473. (PMID: 25394902)
      Mol Cancer Ther. 2014 Jul;13(7):1729-39. (PMID: 24825857)
      J Mol Cell Biol. 2011 Jun;3(3):159-66. (PMID: 21502305)
      Trends Biochem Sci. 2005 Jan;30(1):43-52. (PMID: 15653325)
      Langenbecks Arch Surg. 2014 Feb;399(2):185-97. (PMID: 24297502)
      Int J Biochem Cell Biol. 2013 Mar;45(3):536-45. (PMID: 23262295)
      Oncotarget. 2014 Feb 15;5(3):740-53. (PMID: 24519909)
      Biochim Biophys Acta. 2013 Apr;1830(4):3067-76. (PMID: 23333633)
      Endocr Relat Cancer. 2013 Oct 14;20(6):809-23. (PMID: 24127332)
      Semin Cell Dev Biol. 2012 Jun;23(4):458-64. (PMID: 22309843)
      Oncotarget. 2014 Aug 30;5(16):6611-9. (PMID: 25115394)
      Cancer Cell. 2010 Sep 14;18(3):268-81. (PMID: 20832754)
      Cytokine Growth Factor Rev. 2015 Feb;26(1):7-13. (PMID: 25438737)
      Am J Pathol. 2013 Feb;182(2):350-62. (PMID: 23201134)
      Oncologist. 2007 May;12(5):535-42. (PMID: 17522241)
      J Clin Endocrinol Metab. 2008 May;93(5):1600-8. (PMID: 18270258)
      Endocrinology. 2006 Dec;147(12 ):5699-707. (PMID: 16959844)
      Cancer. 2014 Nov 1;120(21):3287-301. (PMID: 24942936)
      Nat Immunol. 2010 Nov;11(11):1057-62. (PMID: 20935646)
      Cell Tissue Res. 2015 Jan;359(1):125-33. (PMID: 24850276)
      Endocr Relat Cancer. 2009 Mar;16(1):211-24. (PMID: 18984779)
      Exp Mol Pathol. 2013 Aug;95(1):62-7. (PMID: 23685355)
      Dis Markers. 2015;2015:482146. (PMID: 26063957)
      J Clin Invest. 2015 Feb;125(2):824-30. (PMID: 25574842)
      J Natl Cancer Inst. 2010 Jan 20;102(2):127-33. (PMID: 20026813)
    • Contributed Indexing:
      Keywords: HES1; Medullary thyroid cancer; RET; Tumor progression; miR-182
    • Accession Number:
      0 (3' Untranslated Regions)
      0 (MAS1 protein, human)
      0 (MicroRNAs)
      0 (Mirn182 microRNA, human)
      0 (NF-kappa B)
      0 (Proto-Oncogene Mas)
      0 (Receptor, Notch1)
      0 (Transcription Factor HES-1)
      149348-15-2 (HES1 protein, human)
      EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
    • Subject Terms:
      Thyroid cancer, medullary
    • Publication Date:
      Date Created: 20170127 Date Completed: 20170724 Latest Revision: 20211204
    • Publication Date:
      20221213
    • Accession Number:
      PMC5267421
    • Accession Number:
      10.1186/s12943-016-0563-x
    • Accession Number:
      28122586